All In Biotech

Drug Trial Radar · NCT04638751

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jul 1, 2022

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Persephone BiosciencesIndustry
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic cancer. Healthy control subjects without a cancer diagnosis will also be studied, comprised of individuals at high risk for CRC and healthy individuals at low risk for CRC. Risk assessment will be based on family history or past neoplastic findings during CRC screening. Data collected from this study will be used to develop the most effective new therapies, via microbiome optimization, all to the benefit of patients and the physicians treating them. Stool and blood samples will be collected longitudinally and analyzed to determine the impact of gut microbiome composition and function on the immune system and efficacy of the treatment. Currently enrolling the CRC, high risk, and low risk cohorts. Subjects who meet the entry criteria will provide up to 5 samples each of blood and stool over a 2-year period. Approximately 10%-20% of the subjects will provide colon tissue samples, either from research biopsies during Standard of Care (SOC) screening colonoscopy or retained surgical tissue from colectomy. Electronic health records will be obtained at various times for up to 8 years, to collect tumor imaging results and any other updated medical data, with no additional samples collected. In select cases, stool and blood samples will be collected beyond 2 years.

Conditions

  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Triple Negative Breast Cancer
  • Pancreas Cancer

Interventions

  • ImmunotherapyDrug

    Checkpoint inhibitor

  • ChemotherapyDrug

    Any form of chemotherapy

  • CRC surgical resectionProcedure

    Surgical resection to remove colorectal cancer

  • ColonoscopyProcedure

    Standard-of-care colonoscopy for CRC screening

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine whether the microbiome composition can predict progression-free survivalTime frame: 6-12 months
  2. Determine whether the microbiome composition can predict risk for colorectal cancerTime frame: 2-8 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Knowledge Research Center

    Orange, California

  • SDG Clinical Research, Inc

    San Diego, California

  • Persephone Biosciences, Inc.

    San Diego, California

  • L&A Morales Healthcare, Inc

    Miami, Florida

  • Baton Rouge General Medical Center

    Baton Rouge, Louisiana

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Mid-Hudson Medical Research

    New Windsor, New York

  • Kroger Health, The Little Clinic

    Cincinnati, Ohio

  • Southwest Family Medicine Associates

    Dallas, Texas

  • Biopharma Informatic

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.